Oropouche fever has reemerged in Parauapebas and Porto de Moz municipalities, Pará State, Brazil. Serologic analysis (immunoglobulin M-ELISA) and virus isolation confi rmed Oropouche virus (OROV) in both municipalities. Nucleotide sequencing of 2 OROV isolates from each location indicated genotypes I (Parauapebas) and II (Porto de Moz) in Brazil.
O ropouche virus (OROV), the cause of Oropouche fever, belongs to the family Bunyaviridae, genus Orthobunyavirus, Simbu serogroup (1) , and is transmitted between humans in urban areas by the biting midge Culicoides paraensis (2, 3) . This virus was fi rst isolated from febrile forest workers in Trinidad in 1955. The fi rst isolation in Brazil was in 1960 from the blood of a sloth (Bradypus tridactylus) (4) . The epidemic potential of OROV was recognized during an outbreak in Belém, Pará State, Brazil, in 1961, where ≈11,000 persons were infected (4) . Over the past 45 years, many outbreaks of Oropouche fever, ≈500,000 cases, have been described in the Americas. OROV has been isolated in Trinidad, Panama, Peru, and Brazil, and in the past 40 years Oropouche fever has emerged as a public health problem in tropical areas of Central and South America (3) .
Members of the genus Orthobunyavirus have a tripartite, single-stranded, negative-sense RNA genome of small (S), medium (M), and large (L) RNAs that encode nucleocapsid, glycoproteins, and RNA polymerase, respectively. Phylogenetic analysis of nucleocapsid genes of different OROV strains identifi ed 3 distinct genotypes (I, II, and III) currently circulating in Central and South America; genotypes I and II have been detected in the Brazilian Amazon (5) . Recently, an OROV isolate from a marmoset (Callithrix sp.) was characterized as a member of genotype III (6) .
The Study
Two outbreaks of Oropuche fever occurred during 2003 and 2004. The fi rst occurred in April-May 2003 in 2 communities (Vila Sansão, 140 inhabitants, and Vila Paulo Fontelles, 835 inhabitants).in the municipality of Parauapebas (6°4′S, 49°54′W). The second outbreak occurred in July-August 2004 in 1 community (Vila Tapara, 2,000 inhabitants) in the municipality of Porto de Moz (1°45′S, 52°14′W) (Figure 1) .
A total of 125 and 109 serum samples were collected from residents of Parauapebas and Porto de Moz, which represented 12.8% and 5.45% of all inhabitants, respectively. Criteria for sampling were a history of acute fever several weeks before or during the survey or clinical symptoms similar to those of Oropouche fever. All serum samples were analyzed by hemagglutination inhibition (HI) test (7) and immunoglobulin M-ELISA (8) for specifi c HI and IgM antibodies to OROV. HI titers >20 and ELISA results greater than the cut-off value (optical density >0.200) were considered positive (8) .Virus isolation was conducted by intracranial injection of newborn mice with a 1:10 (v/v) suspension of serum samples in phosphate-buffered saline, pH 7.4, as described elsewhere (9) . Fifty-four and 11 serum samples from Parauapebas and Porto de Moz, respectively, were used for virus isolation. Identifi cation of isolates was performed by complement fi xation test as reported (9) . Two OROV strains were isolated from patients in Parauapebas, and 2 strains were isolated from patients in Porto de Moz.
To genetically characterize the viruses, 2 isolates were selected from Parauapebas (Brazil 2003a and Brazil 2003b) and 2 from Porto de Moz (Brazil 2004a and Brazil 2004b). Viral RNA was extracted from Vero cells infected with human samples, and S RNA was amplifi ed by using a 1-step reverse transcription-PCR assay as described (5,6). Phylogenetic trees were constructed for nucleocapsid gene nucleotide sequences by comparison with other OROV nucleocapsid gene sequences in GenBank (Table 1) ; neighbor-joining analysis (10) implemented in Mega version 2.1 (11) was used. Bootstrap analyses were performed on 1,000 replicates to generate confi dence for groupings (12) .
Of 125 serum samples from patients in Parauapebas, HI results were positive for 16 (12.7%) from Vila Sansão, 6 (4.8%) from Paulo Fontelles, and 4 (3.2%) from other localities. IgM was detected in 16 (12.7%), 8 (4.8%), and 6 (4.8%) serum samples from these 3 areas, respectively. Of 117 serum samples from patients in Porto de Moz, 56 (46.7%) had HI antibodies and 61 (52.1%) had IgM to OROV.
A total of 71.9% of female patients in Parauapebas and 59% in Porto de Moz had symptoms suggestive of Oropouche fever. Although all age groups were affected, persons 5-14 years of age had the highest frequency of symptoms (30.4%) and those <1-4 years of age had the lowest frequency (4.8%) ( Table 2) . Symptoms most frequently reported were fever (100%), headache (79.3%), joint pain (68.7%), and muscle pain (30%). Seventy percent of patients reported ≥1 episode of recurrence of fever, characterized by fever, headache, and other symptoms ≈2-3 weeks after onset of initial symptoms (2,3).
Full-length S RNA of the 4 OROV strains contained 754 nt and encoded 2 overlapping open reading frames, the 
Conclusions
Oropouche fever is the second most common arboviral disease (after dengue fever) in the Brazilian Amazon region. From 1960 to 1980, Oropouche fever outbreaks were detected only in Pará State, mainly in Belém and neighboring areas, where thousands of people were infected (2,3). OROV was then detected in other Amazonian states including Amazonas, Amapá, Acre, Rondônia, and Tocantins; and non-Amazonian states, including Maranhão in northeastern Brazil and Tocantins in central Brazil (3, 8) . Recently, OROV isolated from Callithrix sp.in Arinos, Minas Gerais State, southeastern Brazil was characterized as genotype III, which indicated the presence of this genotype in Brazil (6) . OROV from this species has been identifi ed only in Panama (5) . From 1980 to 2005, sporadic cases or self-limited outbreaks of Oropouche fever were reported in areas of the Brazilian Amazon, which suggested silent endemic circulation of the virus (13 (Figure 2) . Recognition of different OROV genotypes in the Brazilian Amazon, as well as new genetic information, is useful for understanding the epidemiology and genetic diversity of this emergent human pathogen. 
